Racial/ethnic and socioeconomic differences in short-term breast cancer survival among women in an integrated health system

American Journal of Public Health

Volumn 105, Issue 5, 2015, Pages 938-946

  Keegan, Theresa H M ^a   Kurian, Allison W ^b   Gali, Kathleen ^c   Tao, Li ^a   Lichtensztajn, Daphne Y ^a   Hershman, Dawn L ^d   Habel, Laurel A ^e   Caan, Bette J ^e   Gomez, Scarlett L ^a  

^a CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN AMERICAN; ANCESTRY GROUP; BREAST NEOPLASMS; CALIFORNIA; CANCER STAGING; CAUCASIAN; DEMOGRAPHY; EPIDEMIOLOGY; ETHNIC GROUP; ETHNOLOGY; FEMALE; HISPANIC; HUMAN; MIDDLE AGED; MORTALITY; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA;

AFRICAN AMERICANS; BREAST NEOPLASMS; CALIFORNIA; CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RESIDENCE CHARACTERISTICS; SOCIOECONOMIC FACTORS;

EID: 84926653381     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2014.302406     Document Type: Article

References (61)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105(3):175-201.
3. Ooi SL, Martinez ME, Li CI. Disparities in breast cancer characteristics and outcomes by race/ethnicity. Breast Cancer Res Treat. 2011;127(3):729-738.
4. Akinyemiju TF, Soliman AS, Copeland G, Banerjee M, Schwartz K, Merajver SD. Trends in breast cancer stage and mortality in Michigan (1992-2009) by race, socioeconomic status, and area healthcare resources. PLoS One. 2013;8(4):e61879.
5. De Santis C, Naishadham D, Jemal A. Cancer statistics for African Americans, 2013. CA Cancer J Clin. 2013;63(3):151-166.
6. Vona-Davis L, Rose DP. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt). 2009;18(6):883-893.
7. Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA. Meta-analysis of survival in African American and White American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol. 2006;24(9):1342-1349.
8. Deshpande AD, Jeffe DB, Gnerlich J, Iqbal AZ, Thummalakunta A, Margenthaler JA. Racial disparities in breast cancer survival: an analysis by age and stage. J Surg Res. 2009;153(1):105-113.
9. Tannenbaum SL, Koru-Sengul T, Miao F, Byrne MM. Disparities in survival after female breast cancer diagnosis: a population-based study. Cancer Causes Control. 2013;24(9):1705-1715.
10. Silber JH, Rosenbaum PR, Clark AS, et al. Characteristics associated with differences in survival among Black and White women with breast cancer. JAMA. 2013;310(4):389-397.
11. Niu X, Pawlish KS, Roche LM. Cancer survival disparities by race/ethnicity and socioeconomic status in New Jersey. J Health Care Poor Underserved. 2010;21(1):144-160.
12. Curtis E, Quale C, Haggstrom D, Smith-Bindman R. Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer. 2008;112(1):171-180.
13. Maskarinec G, Sen C, Koga K, Conroy SM. Ethnic differences in breast cancer survival: status and determinants. Womens Health (Lond Engl). 2011;7(6):677-687.
14. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109(9):1721-1728.
15. Clarke CA, Keegan TH, Yang J, et al. Age-specific incidence of breast cancer subtypes: understanding the Black-White crossover. J Natl Cancer Inst. 2012;104(14):1094-1101.
16. Keegan TH, Press DJ, Tao L, et al. Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women. Breast Cancer Res. 2013;15(5):R95.
17. Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D. Comorbidity and survival disparities among Black and White patients with breast cancer. JAMA. 2005;294(14):1765-1772.
18. Woods LM, Rachet B, Coleman MP. Origins of socio-economic inequalities in cancer survival: a review. Ann Oncol. 2006;17(1):5-19.
19. Keegan TH, Quach T, Shema S, Glaser SL, Gomez SL. The influence of nativity and neighborhoods on breast cancer stage at diagnosis and survival among California Hispanic women. BMC Cancer. 2010;10:603.
20. Gomez SL, Clarke CA, Shema SJ, Chang ET, Keegan TH, Glaser SL. Disparities in breast cancer survival among Asian women by ethnicity and immigrant status: a population-based study. Am J Public Health. 2010;100(5):861-869.
21. Barry J, Breen N. The importance of place of residence in predicting late-stage diagnosis of breast or cervical cancer. Health Place. 2005;11(1):15-29.
22. Dailey AB, Kasl SV, Holford TR, Calvocoressi L, Jones BA. Neighborhood-level socioeconomic predictors of nonadherence to mammography screening guidelines. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2293-2303.
23. Du XL, Fang S, Meyer TE. Impact of treatment and socioeconomic status on racial disparities in survival among older women with breast cancer. Am J Clin Oncol. 2008;31(2):125-132.
24. Nurgalieva ZZ, Franzini L, Morgan RO, Vernon SW, Liu CC, Du XL. Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer. Med Oncol. 2013;30(1):419.
25. Engels EA, Pfeiffer RM, Ricker W, Wheeler W, Parsons R, Warren JL. Use of surveillance, epidemiology, and end results-Medicare data to conduct case-control studies of cancer among the US elderly. Am J Epidemiol. 2011;174(7):860-870.
26. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 suppl): IV-3-IV-18.
27. Kurian AW, Lichtensztajn DY, Keegan TH, et al. Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007. Breast Cancer Res Treat. 2013;137(1):247-260.
28. Williams DR, Kontos EZ, Viswanath K, et al. Integrating multiple social statuses in health disparities research: the case of lung cancer. Health Serv Res. 2012;47(3 pt 2):1255-1277.
29. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
30. Wagner EH, Greene SM, Hart G, et al. Building a research consortium of large health systems: the Cancer Research Network. J Natl Cancer Inst Monogr. 2005;(35):3-11.
31. Gordon N. Similarity of the Adult Kaiser Permanente Membership in Northern California to the Insured and General Population in Northern California: Statistics From the 2007 California Health Interview Survey. Oakland, CA: Kaiser Permanente Division of Research; 2012.
32. Gordon N. A Comparison of Sociodemographic and Health Characteristics of the Kaiser Permanente Northern California Membership Derived From Two Data Sources: The 2008 Member Health Survey and the 2007 California Health Interview Survey. Oakland, CA: Kaiser Permanente Division of Research; 2012.
33. Gordon N. Similarity of the Adult Kaiser Permanente Membership in Northern California to the Insured and General Population in Northern California: Statistics From the 2009 California Health Interview Survey. Oakland, CA: Kaiser Permanente Division of Research; 2012.
34. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8, 769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120-4128.
35. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
36. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
37. Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676-682.
38. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000;92(18):1472-1489.
39. Rocha RL, Hilsenbeck SG, Jackson JG, et al. Insulinlike growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res. 1997;3(1):103-109.
40. Irwin ML, McTiernan A, Bernstein L, et al. Relationship of obesity and physical activity with C-peptide, leptin, and insulin-like growth factors in breast cancer survivors. Cancer Epidemiol Biomarkers Prev. 2005;14(12):2881-2888.
41. Caan BJ, Sweeney C, Habel LA, et al. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes. Cancer Epidemiol Biomarkers Prev. 2014;23(5):725-734.
42. Sweeney C, Bernard PS, Factor RE, et al. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2014;23(5):714-724
43. Bernstein L, Lacey JV Jr. Receptors, associations, and risk factor differences by breast cancer subtypes: positive or negative? J Natl Cancer Inst. 2011;103(6):451-453.
44. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
45. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869-10874.
46. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001;12(8):703-711.
47. McKenzie F, Jeffreys M. Do lifestyle or social factors explain ethnic/racial inequalities in breast cancer survival? Epidemiol Rev. 2009;31:52-66.
48. Burgess DJ, Ding Y, Hargreaves M, Van Ryn M, Phelan S. The association between perceived discrimination and underutilization of needed medical and mental health care in a multi-ethnic community sample. J Health Care Poor Underserved. 2008;19(3):894-911.
49. Masi CM, Gehlert S. Perceptions of breast cancer treatment among African-American women and men: implications for interventions. J Gen Intern Med. 2009;24(3):408-414.
50. Hendren S, Chin N, Fisher S, et al. Patients' barriers to receipt of cancer care, and factors associated with needing more assistance from a patient navigator. J Natl Med Assoc. 2011;103(8):701-710.
51. Mujahid MS, Janz NK, Hawley ST, Griggs JJ, Hamilton AS, Katz SJ. The impact of sociodemographic, treatment, and work support on missed work after breast cancer diagnosis. Breast Cancer Res Treat. 2010;119(1):213-220.
52. Gerend MA, Pai M. Social determinants of Black-White disparities in breast cancer mortality: a review. Cancer Epidemiol Biomarkers Prev. 2008;17(11):2913-2923.
53. Celaya MO, Rees JR, Gibson JJ, Riddle BL, Greenberg ER. Travel distance and season of diagnosis affect treatment choices for women with early-stage breast cancer in a predominantly rural population (United States). Cancer Causes Control. 2006;17(6):851-856.
54. Griggs JJ, Culakova E, Sorbero ME, et al. Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol. 2007;25(3):277-284.
55. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529-537.
56. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992;82(5):703-710.
57. Clegg LX, Reichman ME, Hankey BF, et al. Quality of race, Hispanic ethnicity, and immigrant status in population-based cancer registry data: implications for health disparity studies. Cancer Causes Control. 2007;18(2):177-187.
58. Gomez SL, Glaser SL. Misclassification of race/ethnicity in a population-based cancer registry (United States). Cancer Causes Control. 2006;17(6):771-781.
59. Bauer K, Parise C, Caggiano V. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen consensus statement for early breast cancer. BMC Cancer. 2010;10:228.
60. Patnaik JL, Byers T, Diguiseppi C, Denberg TD, Dabelea D. The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst. 2011;103(14):1101-1111.
61. Søgaard M, Thomsen RW, Bossen KS, Sørensen HT, Nørgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013;5(suppl 1):3-29.